title: Beyond first-line NSCLC therapy: chemotherapy or erlotinib?
authors.affiliation: Instituto de Biomedicina de Sevilla and Hospital Universitario Virgen del Rocío, Seville, Spain. luis.pazares.sspa@juntadeandalucia.es
authors.forename: Luis
authors.initials: L
authors.lastname: Paz-Ares
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride